Author

R. Meng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1 Microbiology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2

Frequent Co-Authors

J. A. Berglund· 2 shared A. Choi· 1 shared A. Jones· 1 shared A. Mahady· 1 shared B. D. Piening· 1 shared B. Fox· 1 shared B. Liu· 1 shared C. Ballesteros-Merino· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

J. A. Berglund

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin

P. K. Reville, I. N. Sheikh, A. Choi, E. Dai, J. Henderson, X. Li, E. Rojas, C. C. Le, C. Okwuchi, M. Devonish, R. Carrio, N. Pate, K. Malley, D. Bangari, J.-A. Givigan, , M. R. Green

The paper identifies dysfunctional CD8 CAR T-cells in rrLBCL tumors and shows that pegenzileukin mitigates this dysfunction, improving CAR T-cell responses.

bioRxiv · Aug 28, 2023 · PreprintImmunology

FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies

D. A. Knorr, R. Leidner, S. Jensen, R. Meng, A. Jones, C. Ballesteros-Merino, R. B. Bell, M. Baez, D. Sprott, C. Bifulco, B. D. Piening, R. Dahan, B. Fox, J. Ravetch

This paper identifies FcyRIIB as an inhibitory Fc receptor limiting Treg depletion by anti-CTLA-4 antibodies and shows Fc engineering can enhance their efficacy.

bioRxiv · Jan 19, 2023 · PreprintImmunology

MBNL1 and RBFOX1 co-regulate alternative splicing events transcriptome-wide through a conserved buffering mechanism

J. A. Berglund, M. Hale, J. A. Ellis, R. Meng, S. McDaniel, A. Mahady, S. Wagner, J. Richardson, O. McConnell, E. T. Wang

This study identifies a conserved buffering mechanism where MBNL1 and RBFOX1 co-regulate alternative splicing by overlapping RNA motifs, reducing the range of splicing outcomes.

bioRxiv · Apr 20, 2021 · PreprintBiochemistry

Autonomous sensing the insulin peptide by an olfactory G protein coupled receptor modulates glucose metabolism

J. Cheng, Z. Yang, X.-Y. Ge, M.-X. Gao, R. Meng, J.-Y. Lin, Z.-M. Tian, Y.-F. Xu, F. Yang, J.-P. Sun, X. Yu

The paper identifies Olfr109 as an olfactory receptor that detects insulin peptides in pancreatic β cells, modulating glucose metabolism and inflammation.

bioRxiv · Dec 18, 2020Physiology

Asian Zika virus isolate significantly changes the transcriptional profile and alternative RNA splicing events in a neuroblastoma cell line

G. Bonenfant, R. Meng, C. Shotwell, J. A. Berglund, C. T. Pager

This study shows that a contemporary ZIKV isolate causes more significant changes in gene expression and alternative splicing compared to other viruses in neuronal cells.

bioRxiv · Jun 5, 2019Microbiology